Skip to main content
Healing / RecoveryVerified

ARA-290

Cibinetide

An 11-amino-acid non-erythropoietic peptide derived from erythropoietin that selectively activates the innate repair receptor, studied for anti-inflammatory and tissue-protective effects, including sarcoidosis-associated small-fiber neuropathy.

ARA-290
Category
Healing / Recovery
Half-life
Short; ~2 min
Common vial
Varies
Regulatory
Investigational

Tracking and educational reference only, on values you enter or import yourself. Not medical advice or a dosing recommendation.

01

Regulatory status

Investigational

This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.

A regulatory status describes paperwork, not safety. An approved compound can still be wrong for a given person, and an unapproved one is neither thereby dangerous nor thereby fine.

02

Half-life

Short; ~2 min (IV), ~10-20 min terminal (subcutaneous). Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.

03

Storage & handling

Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light.

04

References

  • Peer-reviewed EPO-derived receptor pharmacology
  • Phase 2 neuropathy trials

Read the source

Common questions

ARA-290, answered plainly.

01What is ARA-290?+

An 11-amino-acid non-erythropoietic peptide derived from erythropoietin that selectively activates the innate repair receptor, studied for anti-inflammatory and tissue-protective effects, including sarcoidosis-associated small-fiber neuropathy. It is also referred to as Cibinetide. It is listed here under Healing / Recovery as educational reference, which is not a recommendation to use it.

02Is ARA-290 FDA approved?+

Investigational. This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.

03What is the half-life of ARA-290?+

Short; ~2 min (IV), ~10-20 min terminal (subcutaneous). A half-life is an educational pharmacology figure describing how long the body takes to clear half of a substance. It is not a schedule and does not imply one.

04How is ARA-290 stored and handled?+

Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light. Storage conditions come from a manufacturer's own label where one exists, and a compound with no approved label has no agency-reviewed handling instructions at all.

Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.